Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis.

Plain-language guide to PMID 15151263 (2004): double-blind randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 19 patients.

Key Facts

PMID: 15151263
Journal: Journal of nephrology
Year: 2004
Study type: Randomized Controlled Trial
Authors: Kotzmann H et al. (12 authors)

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Who Took Part

The abstract describes 19 patients taking part.

PubMed indexes the participants as middle-aged adults, both men and women.

This study evaluated the effects of a 12-month rhGH therapy on bone metabolism parameters; alkaline phosphatase (AP), osteocalcin (OC), procollagen I carboxyterminal propeptide (PICP), telopeptide ICTP, serum crosslaps, n-terminal propeptide of type III procollagen (PIIINP) and intact parathyroid hormone (iPTH), as well as on BMD of the lumbar spine and the femoral neck in 19 malnourished HD patients (10 females, 9 males) with a mean age of 59.3 +/- 13.4 yrs.

Fourteen patients completed the 12-month study.

How the Study Was Run

The researchers set it up as a randomized and double-blind study.

The patients were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

As a double-blind Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study, the assignments were hidden from both participants and investigators until the end.

What Was Measured

Topics PubMed links to this paper include Absorptiometry, Photon, Bone Density, Bone and Bones, Chronic Kidney Disease-Mineral and Bone Disorder, Collagen Type I, Femur Neck and Human Growth Hormone.

What This Means in Plain Language

The paper is a randomized and double-blind study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 19 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2004 (Journal of nephrology), a journal based in Italy.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.